Answers are grounded in this paper and cite their sources.
Determines safety and efficacy of zeleciment basivarsen in adults with myotonic dystrophy type 1, suggesting potential for functional gains.
Determine the safety and efficacy of zeleciment basivarsen (z-basivarsen, also known as DYNE-101) in adults with myotonic dystrophy type 1 (DM1) in the Phase 1/2 ACHIEVE trial (NCT05481879).
No takes yet. Share an insight, caveat, or question.
Andersson et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: